A second confirmatory, randomized, withdrawal study of INOpulse in patients with Pulmonary Arterial Hypertension (PAH).

Trial Profile

A second confirmatory, randomized, withdrawal study of INOpulse in patients with Pulmonary Arterial Hypertension (PAH).

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Nitric acid (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms INOvation-RW
  • Most Recent Events

    • 07 Aug 2017 According to a Bellerophon Therapeutics media release, the company plans to initiate this study in 2018 with top line results expected in 2019.
    • 09 Jan 2017 New trial record
    • 04 Jan 2017 According to a Bellerophon Therapeutics media release, company anticipates regulatory approval of INOpulse in 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top